This article is more than 5 years old. Information may no longer be current.

FDA approves AcrySof Toric IOL

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

FORT WORTH, Texas — A toric IOL for use in cataract patients with existing astigmatism has been granted U.S. regulatory approval, according to the manufacturer.

Alcon’s AcrySof Toric IOL is based on the original AcrySof design, the company said in a press release announcing the Food and Drug Administration approval of the lens.

“Approval of the AcrySof Toric IOL is an important addition to our AcrySof IOL product portfolio and further demonstrates our commitment to helping cataract surgeons achieve the best possible outcomes for their patients,” said Robert J. Stevens, vice president of surgical products research and development for Alcon.

The company intends to launch the AcrySof Toric IOL in conjunction with the American Society of Cataract and Refractive Surgery meeting in March 2006. Alcon said it was continuing to pursue approval of a blue-light absorbing chromophore to incorporate into the AcrySof Toric lens.